Tag Archives: GSK

Altimmune Topline Ph2 Pemvidutide AUD Data; GSK Q2 ’26 Earnings; New Pfizer Ph1 Oral GLP-1RA Study; Antag Ph2a GIP Antagonist Study; Salubris Ph2 Lp(a) Study

A series of cardiometabolic-related news items has been observed from Altimmune, GSK, Pfizer, Antag Therapeutics, and Shenzhen Salubris Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo’s Wegovy Pill Receives Approval in EU; Gubra Initiates FIH Study for Muscle-Sparing Asset; GSK Initiates Ph3 Efimosfermin Studies in MASH; Fractyl One Year Data; Ascletis Selects Another FDC in Obesity; Rani Topline Ph1 Data; BI H1 2026 Updates

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Gubra, GSK, Fractyl Health, Ascletis Pharma, Rani Therapeutics, and Boehringer Ingelheim. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Sanofi to Pull Tzield Application from CNPV Program; Zealand Q1 ’26 Earnings; GSK Targets ALK7; Lilly Expands US Manufacturing Investment; Roche Acquires PathAI

A series of cardiometabolic-related news items has been observed from Sanofi, Zealand Pharma, GSK, Lilly, and Roche. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

AZ, AbbVie, Regeneron, Ionis, and GSK Q1 ’26 Earnings; Zealand and Roche to Advance Petrelintide to Ph3

A series of cardiometabolic-related news items has been observed from AstraZeneca, AbbVie, Regeneron, Ionis, GSK, and Zealand Pharma/Roche. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Ascletis Completes Ph2 Enrollment for ASC30 in T2DM; GSK’s Efimosfermin Breakthrough Therapy and PRIME Designations; Tandem Control-IQ+ Pregnancy Indication; Tandem Mobi Correction; Sagimet Business Updates and Stock Pricing

A series of cardiometabolic-related news items has been observed from Ascletis Pharma, GSK, Tandem Diabetes, and Sagimet Biosciences. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Hims Launches Compounded Sema Pill; Novo London, AbbVie, GSK, and Novartis Q4 ’25 Earnings; Stelo Smart Meal Logging Updates; Abbott FDA Warning Letter and Class I Recall; Rare Pediatric PRV Program Reauthorized; Sciwind Ph3 OSA Study

A series of cardiometabolic-related news items has been observed from Hims & Hers, Novo Nordisk, AbbVie, GSK, Novartis, Dexcom, Abbott, the White House, and Sciwind Biosciences. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Pfizer/Novo Battle Escalates; Lilly Registers Another ORC Study; New Lilly Orfor Manufacturing Site; GSK Ph3 MASH Program

A series of cardiometabolic-related news items have been observed from Pfizer/Metsera, Lilly, and GSK. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo Partners with Septerna for Obesity Drug Development; GSK Acquires MASH Asset from Boston Pharma; Sernova Interim Cell Pouch Results; Found Integrates with LillyDirect and NovoCare; Cytokinetics Ph3 HCM Results; Lexicon, Fractyl, and Scholar Rock Q1 ’25 Earnings

A series of cardiometabolic-related news items has been observed from: Novo Nordisk/Septerna, GSK/Boston Pharmaceuticals, Sernova Biotherapeutics, Found, Cytokinetics, Lexicon Pharmaceuticals, Fractyl Health, and Scholar Rock. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Sanofi Q3 ’23 Earnings; Additional Sernova Cell Pouch Data; GSK Initiates New Ph2a NASH Study

Three cardiometabolic-related news items have been observed: Sanofi hosted its Q3 ’23 earnings call (press release; slides; infographic); Sernova announced positive interim results from its ongoing Ph1/2 Cell Pouch study (view press release); and GSK initiated a new Ph2 study evaluating GSK4532990 in participants with NASH and suspected NASH (view CT.gov record). Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Lilly Poised to Own the Obesity Market; ADA 2023 Key Press Releases (June 26)

On the last day of ADA 2023, nine cardiometabolic-related news items were observed from Lilly, Pfizer, Fractyl Health, Zealand Pharma, Vertex, Sernova, Senseonics, Dario, and GSK. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.

Already a member? Log in here